bioAffinity Technologies, Inc.

BIAF Healthcare Diagnostics & Research

In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.

3.73 0.23 −5.81%
Market cap
$5.1M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
2/9
Altman Z
−10.54
Beneish M
−5.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 2 2 3
ROE
(245.18%) (301.83%) (622.65%) (1,860.15%)
ROA
(162.88%) (170.65%) (235.39%) (245.51%)
ROIC
(458.54%) (438.42%) (613.56%) (408.67%)
Return on Tangible Assets
(224.78%) (302.76%) (1,131.70%) (1,013.64%)
Average Days of Receivables
24.18 32.10 44.19 55.35
Free Cash Flow per Share
(119.65) (81.79) (36.46) (33.16)
Free Cash Flow
(8.51) (9.39) (10.93) (11.56)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026